SPS
CORT icon

Susquehanna Portfolio Strategies’s Corcept Therapeutics CORT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
211,017
+33,870
+19% +$2.05M 0.29% 96
2026
Q1 		$7.14M Buy
+177,147
New +$6.62M 0.11% 246
2024
Q1 		– Sell
-10,950
Closed -$356K – 819
2023
Q4 		$356K Buy
+10,950
New +$301K 0.01% 830

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna Portfolio Strategies's CORT Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Corcept Therapeutics (CORT) stake by 19% in Q2 2026, buying an estimated $2.05M and bringing the position to 211,017 shares worth $18.3M. The position accounts for 0.29% of the portfolio, ranked #96.

Susquehanna Portfolio Strategies first reported a position in CORT in Q4 2023 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Susquehanna Portfolio Strategies held 211,017 shares of Corcept Therapeutics worth $18.3M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 33,870 Corcept Therapeutics shares in Q2 2026, an estimated $2.05M.
  • Corcept Therapeutics made up 0.29% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #96 holding.
  • Susquehanna Portfolio Strategies first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.